As of today (2024-05-21), Paion Ag's share price is $0.0251.
Paion Ag's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.93. Hence, Paion Ag's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Paion Ag's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Paion Ag's highest Price-to-Free-Cash-Flow Ratio was 181.89. The lowest was 0.03. And the median was 8.87.
PAIOF's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.19 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 13 years, Paion Ag's highest 3-Year average Free Cash Flow per Share Growth Rate was 41.60% per year. The lowest was -57.10% per year. And the median was 5.70% per year.
Paion Ag Price-to-Free-Cash-Flow Historical Data
The historical data trend for Paion Ag's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Paion Ag's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paion Ag's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Paion Ag's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Paion Ag's Price-to-Free-Cash-Flow falls into.
Paion Ag Price-to-Free-Cash-Flow Calculation
Paion Ag's Price-to-Free-Cash-Flow ratio for today is calculated as
Paion Ag's Share Price of today is $0.0251.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion Ag's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Paion Ag (OTCPK:PAIOF) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Paion Ag Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Paion Ag's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PAIOF has been successfully added to your 